Stool Biomarkers as a Clue for Developing Crohn's Disease in Idiopathic Pyoderma Gangrenosum Patients.
作者信息
Dawood Marwan, Khamaysi Ziad, Avitan-Hersh Emily
机构信息
Department of Dermatology, Rambam Health Care Campus, Haifa, Israel.
The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
出版信息
Int J Dermatol. 2025 Aug;64(8):1515-1516. doi: 10.1111/ijd.17703. Epub 2025 Mar 26.
Abstract
摘要
相似文献
1
Stool Biomarkers as a Clue for Developing Crohn's Disease in Idiopathic Pyoderma Gangrenosum Patients.粪便生物标志物作为特发性坏疽性脓皮病患者发生克罗恩病的线索
Int J Dermatol. 2025 Aug;64(8):1515-1516. doi: 10.1111/ijd.17703. Epub 2025 Mar 26.
2
Pyoderma gangrenosum at the parastomal site in patients with Crohn's disease.克罗恩病患者造口旁部位的坏疽性脓皮病
Arch Surg. 1984 Oct;119(10):1186-8. doi: 10.1001/archsurg.1984.01390220064014.
3
Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease.50例克罗恩病患者的结节性红斑和坏疽性脓皮病
Can J Gastroenterol. 2005 Oct;19(10):603-6. doi: 10.1155/2005/323914.
4
Integrating Gut Microbiome and Metabolomics with Magnetic Resonance Enterography to Advance Bowel Damage Prediction in Crohn's Disease.整合肠道微生物组和代谢组学与磁共振肠造影术以推进克罗恩病肠道损伤预测
J Inflamm Res. 2025 Jun 11;18:7631-7649. doi: 10.2147/JIR.S524671. eCollection 2025.
5
Erythema nodosum progressing to pyoderma gangrenosum as a complication of Crohn's disease.结节性红斑进展为坏疽性脓皮病，作为克罗恩病的一种并发症。
Postgrad Med J. 1983 Dec;59(698):791-3. doi: 10.1136/pgmj.59.698.791.
6
Fecal Calprotectin is a Useful Biomarker for Defining Small Bowel Endoscopic Remission in Crohn's Disease Without Active Colonic Lesions: A Prospective Multicenter Study from the IBD-Quality Team.粪便钙卫蛋白是用于定义无活动性结肠病变的克罗恩病小肠内镜缓解的有用生物标志物：来自炎症性肠病质量团队的一项前瞻性多中心研究。
Inflamm Bowel Dis. 2025 Jun 30. doi: 10.1093/ibd/izaf138.
7
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.与溃疡性结肠炎相关的泛发性坏疽性脓皮病：英夫利昔单抗和硫唑嘌呤治疗成功
Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.
8
Histologic scoring indices for evaluation of disease activity in Crohn's disease.用于评估克罗恩病疾病活动度的组织学评分指标。
Cochrane Database Syst Rev. 2017 Jul 21;7(7):CD012351. doi: 10.1002/14651858.CD012351.pub2.
9
Vedolizumab (Entyvio®) for the Treatment of Pyoderma Gangrenosum in a Crohn's Disease Patient.维多珠单抗（恩特维尤®）用于治疗一名克罗恩病患者的坏疽性脓皮病。
Cureus. 2021 Jan 8;13(1):e12582. doi: 10.7759/cureus.12582.
10
Assessment of Treatment Response in Known Crohn's Disease-A Prospective Blinded Study Comparing the Diagnostic Accuracy of Intestinal Ultrasound, Magnetic Resonance Enterocolonography, Panenteric Capsule Endoscopy, and Fecal Calprotectin.已知克罗恩病治疗反应的评估——一项前瞻性双盲研究，比较肠道超声、磁共振小肠造影、全肠道胶囊内镜和粪便钙卫蛋白的诊断准确性
Inflamm Bowel Dis. 2024 Nov 4. doi: 10.1093/ibd/izae254.
本文引用的文献
1
Calprotectin in inflammatory bowel disease.炎症性肠病中的钙卫蛋白
Clin Chim Acta. 2020 Nov;510:556-565. doi: 10.1016/j.cca.2020.08.025. Epub 2020 Aug 18.
2
Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.瑞士炎症性肠病队列中肠外表现相对于炎症性肠病诊断时间的出现时间顺序。
Inflamm Bowel Dis. 2015 Aug;21(8):1794-800. doi: 10.1097/MIB.0000000000000429.
3
Pyoderma gangrenosum in inflammatory bowel disease: the experience at Mater Health Services' Adult Hospital 1998-2009.炎症性肠病相关性坏疽性脓皮病：1998 年至 2009 年 Mater 卫生服务成人医院的经验。
J Crohns Colitis. 2011 Apr;5(2):148-51. doi: 10.1016/j.crohns.2010.10.006. Epub 2011 Feb 22.
4
Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients.结节性红斑和坏疽性脓皮病在炎症性肠病中的意义：一项对2402例患者的队列研究
Medicine (Baltimore). 2008 Sep;87(5):281-293. doi: 10.1097/MD.0b013e318187cc9c.
5
Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients.坏疽性脓皮病的治疗建议：基于350多名患者的文献循证综述
J Am Acad Dermatol. 2005 Aug;53(2):273-83. doi: 10.1016/j.jaad.2004.10.006.
Zotero 插件